Data as of May 17
| +0.20 / +3.51%|
The 5 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 3.00. The median estimate represents a +18.85% increase from the last price of 5.89.
The current consensus among 8 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.